Multi-center evaluation of a user-friendly lateral flow assay to determine IP-10 and CCL4 levels in blood of TB and non-TB cases in Africa

Corstjens, Paul L. A. M.; Fat, Elisa M. Tjon Kon; Dood, Claudia J. de; Schip, Jolien J. van der Ploeg-van; Franken, Kees L. M. C.; Chegou, Novel N.; Sutherland, Jayne S.; Howe, Rawleigh; Mihret, Adane; Kassa, Desta; Vyver, Marieta van der; Sheehama, Jacob; Simukonda, Felanji; Mayanja‐Kizza, Harriet; Ottenhoff, Tom H. M.; Walzl, Gerhard; Geluk, Annemieke

doi:10.1016/j.clinbiochem.2015.08.013

Cited by 48 publications

(50 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To allow appropriate point-of-care testing in remote settings, the final prototype would include a lightweight portable strip reader with built-in software including an algorithm to interpret results obtained with lateral flow (LF) strips comprising multiple cytokine test lines. Such a device is an improvement of the recently investigated up-converting phosphor lateral flow (UCP-LF) platform in a multisite evaluation study in Africa 40. A cheap point-of-care test, with a high NPV of 96.4%, would identify patients who require confirmatory testing with gold standard tests such as culture and the GeneXpert, which are technically more demanding and have to be conducted in a centralised manner.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB

Chegou

Sutherland

Malherbe

et al. 2016

Thorax

Self Cite

134

161

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB

Chegou

Sutherland

Malherbe

et al. 2016

Thorax

Self Cite

134

161

View full text Add to dashboard Cite

“…Early evidence suggests that these responses will be informative before culture or microscopic conversion is currently detected [78,79,89,90]. Thus, as measuring the response of host biomarker kinetics has the potential to be both simple and rapid [91], measuring biomarkers deserve attention. Moreover, biomarkers can also be applicable to atypical cases (non-pulmonary and infections in children).…”

Section: Potential Role Of Host-derived Biomarkers In Treatment Guidancementioning

confidence: 99%

Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers

Alffenaar

Akkerman

Anthony

et al. 2016

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Introduction: Success rates for treatment of extensively drug resistant tuberculosis (XDR-TB) are low due to limited treatment options, delayed diagnosis and inadequate health care infrastructure. Areas covered: This review analyses existing programmes of prevention, diagnosis and treatment of XDR-TB. Improved diagnostic procedures and rapid molecular tests help to select appropriate drugs and dosages. Drugs dosages can be further tailored to the specific conditions of the patient based on quantitative susceptibility testing of the M. tuberculosis isolate and use of therapeutic drug monitoring. Pharmacovigilance is important for preserving activity of the novel drugs bedaquiline and delamanid. Furthermore, biomarkers of treatment response must be developed and validated to guide therapeutic decisions. Expert commentary: Given the currently poor treatment outcomes and the association of XDR-TB with HIV in endemic regions, a more patient oriented approach regarding diagnostics, drug selection and tailoring and treatment evaluation will improve treatment outcome. The different areas of expertise should be covered by a multidisciplinary team and may involve the transition of patients from hospitalized to home or community-based treatment.

show abstract

“…Unlike bacterial-derived markers such as LAM, which is one of the most promising bacterial derived biomarkers, which are still undetectable in most infected patients. [100,101] In fact, IP-10 is a particularly interesting treatment response biomarker as it has been shown to be stable in dried plasma spots [64] and is present at high levels that are measurable with the new generation of simple near patient assays, [102] which should facilitate rapid repeated costs effective measurement. IP10, however, measured at a single-time point cannot specifically identify TB, nor distinguish between TB and latent-TB infection.…”

Section: Biomarkersmentioning

confidence: 99%

Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis

Zuur

Bolhuis

Anthony

et al. 2016

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

Introduction: Tuberculosis remains a global health problem and pharmacokinetic variability has been postulated as one of the causes of treatment failure and acquired drug resistance. New developments enable implementation of therapeutic drug monitoring, a strategy to evaluate drug exposure in order to tailor the dose to the individual patient, in tuberculosis treatment. Areas covered: Literature on pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs was explored to evaluate the effect of drug exposure in relation to drug susceptibility, toxicity and efficacy. New, down-sized strategies, like dried blood spot analysis and limited sampling strategies are reviewed. In addition, molecular resistance testing of Mycobacteria tuberculosis, combining a short turn-around time with relevant information on drug susceptibility of the causative pathogen was explored. Newly emerging host biomarkers provide information on the response to treatment. Expert opinion: Therapeutic drug monitoring can minimize toxicity and increase efficacy of tuberculosis treatment and prevent the development of resistance. Dried blood spot analysis and limited sampling strategies, can be combined to provide us with a more patient friendly approach. Furthermore, rapid information on drug susceptibility by molecular testing, and information from host biomarkers on the bacteriological response, can be used to further optimize tuberculosis treatment. ARTICLE HISTORY

show abstract

Multi-center evaluation of a user-friendly lateral flow assay to determine IP-10 and CCL4 levels in blood of TB and non-TB cases in Africa

Cited by 48 publications

References 32 publications

Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB

Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB

Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers

Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis

Contact Info

Product

Resources

About